Orbit Biotech

orbitbiotech.com

Estd in 2006, Orbit Biotech is a flagship biotech division of Zodiac Brand Space Pvt. Ltd. an ISO 9001:2008 certified company. The company is focussed on its research in Probiotics and the team has successfully completed many research projects funded by Department of Biotechnology (DBT), Govt. of India. Several in-house research projects aiming at developing state of the art probiotic applications are under process. The company is pioneer in training biotech students and professionals aiming at creating a skilled biotech professionals though its programs. Our aspiration is to provide biotechnology solutions by finding better methods of applications and work actively to promote collaborations between all parties in biotechnological industry in order to achieve our common goal of global competence. Our research and technology leads to the discovery of new and innovative products.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

NORDIC BIOSCIENCE AND ROCHE DIAGNOSTICS STRENGTHEN COLLABORATION FOR DEVELOPMENT OF BIOMARKERS FOR CHRONIC DISEASES

Nordic Bioscience | June 17, 2022

news image

Nordic Bioscience, a growing biomarker company, today announced the strengthening of its ongoing collaboration with Roche Diagnostics for the development of proprietary biomarkers involved in tissue breakdown and build-up. Nordic Bioscience is a world leader in Extra Cellular Matrix (ECM) biomarker development that can provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.<...

Read More

Industrial Impact

ADAPTIVE BIOTECHNOLOGIES ANNOUNCES NEW DATA DEMONSTRATING IMMUNOSEQ® TECHNOLOGY CAN IDENTIFY T-CELL RECEPTORS ASSOCIATED WITH CROHN’S DISEASE

Adaptive Biotechnologies | February 19, 2022

news image

Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, presented data on T-cell receptor (TCR) sequences associated with Crohn’s disease (CD) during an oral presentation today at the 17th Congress of European Crohn’s and Colitis Organisation (ECCO) being held virtually February 16-19. The study identified and characterized TCR sequences associ...

Read More

Medical

MISSION BIO ANNOUNCED THE LAUNCH OF FIRST SINGLE-CELL GENOMICS SOLID TUMOR SOLUTION ON THE TAPESTRI PLATFORM

Mission Bio | March 30, 2022

news image

Mission Bio, Inc., a pioneer in high-throughput single-cell DNA and multi-omics research, announced the commercial availability of the Tapestri Solution for Solid Tumor Research. On the Tapestri Platform, this new end-to-end single-cell DNA sequencing process comprises a nuclei isolation prep technique, pre-designed research panels for breast cancer and glioblastoma multiforme, and an enhanced single-cell copy number variation (CNV) bioinformatic analysis tool. Mission Bio currently covers solid...

Read More

Cell and Gene Therapy

NEW STUDY HIGHLIGHTS CELL AVIDITY'S POWER TO PROVIDE INSIGHTS INTO THE ROBUSTNESS OF T CELL ACTIVATION

LUMICKS | March 24, 2022

news image

LUMICKS, a next generation life science tools company, today announced that a research study published in Cellular and Molecular Life Sciences from the Radboud University Medical Center, led by researchers in the team of Professor G. J. Adema, detailed a novel method to study lead compound effects on immune cell interactions by employing LUMICKS' z-Movi® Cell Avidity Analyzer. The interaction between dendritic cells (DCs) and T cells is a critical step in the activation of...

Read More
news image

Medical

NORDIC BIOSCIENCE AND ROCHE DIAGNOSTICS STRENGTHEN COLLABORATION FOR DEVELOPMENT OF BIOMARKERS FOR CHRONIC DISEASES

Nordic Bioscience | June 17, 2022

Nordic Bioscience, a growing biomarker company, today announced the strengthening of its ongoing collaboration with Roche Diagnostics for the development of proprietary biomarkers involved in tissue breakdown and build-up. Nordic Bioscience is a world leader in Extra Cellular Matrix (ECM) biomarker development that can provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.<...

Read More
news image

Industrial Impact

ADAPTIVE BIOTECHNOLOGIES ANNOUNCES NEW DATA DEMONSTRATING IMMUNOSEQ® TECHNOLOGY CAN IDENTIFY T-CELL RECEPTORS ASSOCIATED WITH CROHN’S DISEASE

Adaptive Biotechnologies | February 19, 2022

Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, presented data on T-cell receptor (TCR) sequences associated with Crohn’s disease (CD) during an oral presentation today at the 17th Congress of European Crohn’s and Colitis Organisation (ECCO) being held virtually February 16-19. The study identified and characterized TCR sequences associ...

Read More
news image

Medical

MISSION BIO ANNOUNCED THE LAUNCH OF FIRST SINGLE-CELL GENOMICS SOLID TUMOR SOLUTION ON THE TAPESTRI PLATFORM

Mission Bio | March 30, 2022

Mission Bio, Inc., a pioneer in high-throughput single-cell DNA and multi-omics research, announced the commercial availability of the Tapestri Solution for Solid Tumor Research. On the Tapestri Platform, this new end-to-end single-cell DNA sequencing process comprises a nuclei isolation prep technique, pre-designed research panels for breast cancer and glioblastoma multiforme, and an enhanced single-cell copy number variation (CNV) bioinformatic analysis tool. Mission Bio currently covers solid...

Read More
news image

Cell and Gene Therapy

NEW STUDY HIGHLIGHTS CELL AVIDITY'S POWER TO PROVIDE INSIGHTS INTO THE ROBUSTNESS OF T CELL ACTIVATION

LUMICKS | March 24, 2022

LUMICKS, a next generation life science tools company, today announced that a research study published in Cellular and Molecular Life Sciences from the Radboud University Medical Center, led by researchers in the team of Professor G. J. Adema, detailed a novel method to study lead compound effects on immune cell interactions by employing LUMICKS' z-Movi® Cell Avidity Analyzer. The interaction between dendritic cells (DCs) and T cells is a critical step in the activation of...

Read More